ResearcherUniversity of DelawareNo recent work listed
Shruti Lal
Matched on ORCID iD 0009-0008-4517-3147; OpenAlex author ID A5102876366. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper
Papers 6
- Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. First author DOI 10.1158/0008-5472.can-17-0015↗
- WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Co-author DOI 10.1038/srep33323↗
- MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. First author DOI 10.1158/1541-7786.mcr-14-0199↗
- HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-13-1915↗
- dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 t… Co-author DOI 10.4161/cbt.28413↗
- Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Co-author DOI 10.1158/1541-7786.mcr-12-0699↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jonathan Robert Brody · 6 shared papers, 2013–2017 · strength 0.25
- Paper WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. DOI 10.1038/srep33323↗
- Paper Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. DOI 10.1158/0008-5472.can-17-0015↗
- Paper MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-14-0199↗
- Jordan Michael Winter · 6 shared papers, 2013–2017 · strength 0.25
- Paper WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. DOI 10.1038/srep33323↗
- Paper Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. DOI 10.1158/0008-5472.can-17-0015↗
- Paper MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-14-0199↗
- Charles J. Yeo · 6 shared papers, 2013–2017 · strength 0.25
- Paper WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. DOI 10.1038/srep33323↗
- Paper Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. DOI 10.1158/0008-5472.can-17-0015↗
- Paper MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-14-0199↗
- Masaya Jimbo · 4 shared papers, 2014–2017 · strength 0.17
- Paper Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. DOI 10.1158/0008-5472.can-17-0015↗
- Paper MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-14-0199↗
- Paper HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. DOI 10.1158/0008-5472.can-13-1915↗
- Richard Andrew Burkhart · 4 shared papers, 2013–2015 · strength 0.14
- Paper MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-14-0199↗
- Paper HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. DOI 10.1158/0008-5472.can-13-1915↗
- Paper dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-inst… DOI 10.4161/cbt.28413↗
- Saswati N. Chand · 2 shared papers, 2016–2017 · strength 0.11
- Mahsa Zarei · 2 shared papers, 2016–2017 · strength 0.11
- Agnieszka Katarzyna Witkiewicz · 3 shared papers, 2013–2015 · strength 0.10
- Paper MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. DOI 10.1158/1541-7786.mcr-14-0199↗
- Paper dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-inst… DOI 10.4161/cbt.28413↗
- Paper Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell … DOI 10.1158/1541-7786.mcr-12-0699↗
- Fernando F. Blanco · 2 shared papers, 2015–2017 · strength 0.10
- Christine A. Iacobuzio–Donahue · 2 shared papers, 2014–2015 · strength 0.08
- Renée M. Tholey · 2 shared papers, 2013–2015 · strength 0.07
- Michael Jon Pishvaian · 1 shared paper, 2016 · strength 0.06
- Seth J. Parker · 1 shared paper, 2017 · strength 0.05
- Ali Vaziri Gohar · 1 shared paper, 2017 · strength 0.05
- Christian M. Metallo · 1 shared paper, 2017 · strength 0.05
- Avinoam Nevler · 1 shared paper, 2017 · strength 0.05
- Carmella Romeo · 1 shared paper, 2014 · strength 0.04
- Vikram Bhattacharjee · 1 shared paper, 2014 · strength 0.04
- Isidore Rigoutsos Computational · 1 shared paper, 2014 · strength 0.04
- Tim J. Yen · 1 shared paper, 2014 · strength 0.04
- Danielle M. Pineda · 1 shared paper, 2014 · strength 0.03
- Myriam Gorospe · 1 shared paper, 2014 · strength 0.03
- Florencia M. McAllister · 1 shared paper, 2014 · strength 0.03
- Daniel A. Laheru · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.